LGG
PFE icon

Luts & Greenleigh Group’s Pfizer PFE Stock Holding History

Luts & Greenleigh Group’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Buy
+7,355
New +$196K 0.16% 88
2024
Q4 		– Sell
-6,997
Closed -$202K – 82
2024
Q3 		$202K Buy
+6,997
New +$204K 0.19% 84

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Luts & Greenleigh Group's PFE Position: Q1 2026 in Review

Luts & Greenleigh Group opened a new position in Pfizer (PFE) in Q1 2026: 7,355 shares worth $207K. The stake represents 0.16% of the portfolio and ranks #88 among its holdings. This is a return to the name: Luts & Greenleigh Group previously reported a position in PFE as recently as Q3 2024.

Luts & Greenleigh Group first reported a position in PFE in Q3 2024 and has held it in 2 quarters since. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Luts & Greenleigh Group held 7,355 shares of Pfizer worth $207K as of Q1 2026.
  • Pfizer was a new Luts & Greenleigh Group position in Q1 2026.
  • Pfizer made up 0.16% of Luts & Greenleigh Group's portfolio in Q1 2026, its #88 holding.
  • Luts & Greenleigh Group first reported a position in Pfizer in Q3 2024 and has held it in 2 quarters since.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Luts & Greenleigh Group's 13F filing for Q1 2026, filed 5 May 2026.